ASH News Daily - Saturday, December 10, 2011 - (Page A-18)
Page A–18
®
Quality
«« From Page A-15
than the unintended consequence
of negatively impacting clinical performance
measurements of physicians
who choose to care for patients
with SCD,” Dr. Lottenberg said. For
example, a hospital re-admission
within 30 days of discharge, a recently
adopted quality indicator for
SCD, may actually be a medically
necessary admission for a patient
with SCD and should not be considered
a poor quality indicator.
Dr. Richard Larson, University
of Chicago, will take a similar approach
in his presentation. Dr.
Larson will use a case of newly diagnosed
acute myelogenous leukemia
to illustrate how the use of the
published guidelines from both the
European Leukemia Network and
the NCCN can help clinicians arrive
at the most precise diagnosis
and thus the best treatment options
for their patients. His application
of quality to clinical practice will
be focused on ordering and evaluating
the essential diagnostic tests
and avoiding duplicative or unnecessary
testing.
Finally, Dr. Richard White, UC
Attendees arrive
at the San Diego
Convention Center
for the start of the
53rd ASH Annual
Meeting and
Exposition.
Davis School of Medicine, will discuss
the importance and application
of quality indicators in the inpatient
CLL
«« From Page B-16
recognition that even patients
with longer remissions, up to
several years after conventional
immune-chemotherapy, have
poor subsequent treatment response
and survival. Dr. Brown
will discuss the role of conventional
therapies, such as alemtuzumab,
the increasing evidence
for and use of allogeneic hema-
setting. He will address the topic,
“Prevention of Venous Thromboembolism
in Hospitalized Patients:
Current Quality Indicators.” As
thromboprophylaxis has so significantly
changed in the inpatient setting
in the last decade due to several
large trials, the application of these
results to quality indicators is more
important than ever.
There are still many unanswered
questions in the field of quality in
hematology. It will become increasingly
important to develop accurate
quality indicators, especially as it
appears that these may soon be tied
to reimbursement.
Dr. Brandow indicated no relevant
conflicts of interest.
topoietic stem cell transplantation
in these patients, and the
promise of the novel therapies
that are currently in development
and being evaluated in
clinical trials for CLL. This
session will repeated on Sunday,
December 11, from 7:30 to
9:00 a.m., in Hall AB of the San
Diego Convention Center.
Dr. Bishop indicated no relevant
conflicts of interest.
ASH NEWS DAILY
Saturday, December 10, 2011
Table of Contents for the Digital Edition of ASH News Daily - Saturday, December 10, 2011
ASH News Daily - Saturday, December 10, 2011
https://www.nxtbookmedia.com